| abstract |
The present invention provides an isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises an extracellular antigen binding domain, comprising an antibody or antibody fragment that binds to a CXC chemokine receptor protein of type 5 (CXCR5). The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and / or B cells, and / or pathogenic T cells and / or follicular T helper cells, particularly non-pathogenic lymphoma. mature B-cell Hodgkin's lymphocyte (B-NHL), non-Hodgkin's lymphoma with T lymphocytes, or an autoimmune disease dependent on autoantibodies, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis. |